ASessment in Ankylosing Spondylitis (ASAS) international working group: A model for psoriatic arthritis and psoriasis?

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Van Der Heijde, D ^a,g   Braun, J ^b,c   Landewe R ^a   Davis, J ^d   Sieper, J ^e   Van Der Linden, S ^a   Dougados, M ^f  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e German Rheumatism Research Center   (Germany)

^f University of Paris ^*  (France)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOLOGIC AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; CLINICAL RESEARCH; CONFERENCE PAPER; CONSENSUS; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; HEALTH CARE ORGANIZATION; HUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS;

ARTHRITIS, PSORIATIC; HUMANS; INTERNATIONAL COOPERATION; MODELS, ORGANIZATIONAL; PSORIASIS; SPONDYLITIS, ANKYLOSING;

EID: 14244262463     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.030858     Document Type: Conference Paper

References (6)

1. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets or endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
2. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
3. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
4. Pham T, van der Heijde D, Calin A, Khan MA, van der Linden S, Bellamy N, et al. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rneum Dis 2003;62:812-16.
5. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, ASAS Working Group, et al. International ASAS consensus statement (or the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rneum Dis 2003;62:817-24.
6. van der Heijde D, van der Linden S, Dougados M, Bellamy N, Russell AS, Edmonds J. Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 1999;26:1003-5.